PHA Classroom banner

>>Back to All Recordings

>>Back to About PH Recordings
>>Back to 2012 Conference Session Recordings

Session Recording from PHA's 2012 10th International PH Conference
Infused Prostacyclins

June 24, 2012

Prostacyclins (epoprostenol, treprostinil) are among the most potent and effective therapies for patients with advanced pulmonary arterial hypertension. However, there are side-effects and complications of these therapies due to their unique delivery systems. This session will review the data with the multiple infused prostacyclins currently available, focusing on patient selection and management of side effects and complications.

Presenter Information

Vallerie McLaughlin, MD, University of Michigan, Ann Arbor, Mich. (Chair); Wendy Hill, MSN, NP-C, VA Greater LA Healthcare System/UCLA, Los Angeles, Calif.; Robert Schilz, DO, PhD, Case Western University School of Medicine, Cleveland, Ohio; Victor Tapson, MD, FCCP, FRCP, Duke University Medical Center, Durham, N.C.








Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. United Therapeutics Corporation Bayer HealthCare
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.


FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2015 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.